Rather Abid, Jena Ashok Kumar, Sarkar Soumya, Sethi Alok Kumar
Senior Resident, Department of Dentistry, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Professor, Department of Dentistry, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
J Oral Maxillofac Surg. 2025 Apr;83(4):476-484. doi: 10.1016/j.joms.2024.12.002. Epub 2024 Dec 4.
Transdermal buprenorphine is used for the management of postoperative pain. Its effectiveness for the postoperative pain management following mandibular resection and reconstruction has yet to be evaluated.
To evaluate the efficacy of transdermal buprenorphine patch (TBP) in managing postoperative pain after mandibular resection and reconstruction with anterior iliac crest graft.
STUDY DESIGN, SETTING AND SAMPLE: This triple-blinded, randomized controlled trial included 30 subjects in the age range of 18 to 60 years with benign mandibular pathologies. Subjects visiting the outpatient department of the Dept. of Dentistry, All India Institute of Medical Sciences, Bhubaneswar, India, were included in the study. Subjects with known allergies to any drugs, using sedatives, alcohol, pregnant and lactating mothers, and with respiratory problems were excluded.
The predictor variable was postoperative pain management and subjects were randomly assigned to TBP or a placebo patch group.
It was the postoperative pain, which was measured by visual analog scale (VAS) for 7 consecutive days. Secondary outcome variables were requirement of rescue analgesics and drug-related adverse effects.
Age at surgery, sex, diagnosis, duration of the operation, and amount of fentanyl used during the operation were covariates.
Descriptive statistics, Mann-Whitney U test, χ, repeated measures analysis of variance, and post-hoc analysis (Bonferroni test) were used. A P value <.05 was considered a level of statistical significance.
Thirty subjects were randomly allocated to TBP and control group. The mean VAS score during the study period was 0.8 ± 2.37, and 3.49 ± 2.37 in TBP and control group subjects respectively (P < .001). Compared to control group, the mean VAS score in TBP group subjects were significantly less till the end of postoperative day 4 (P < .001). The mean rescue analgesic requirement during the postoperative period was 5.33 ± 15.8 mg and 47.6 ± 37.7 mg in the TBP and control group subjects, respectively (P < .001). Nausea was the most common drug-related adverse effect in both the group subjects (46.7%) (P > .9).
The highest VAS score in TBP group subjects was 1.53 ± 0.92 on the morning of postoperative day 1, whereas it was 6.47 ± 1.3 at 6 hours after operation in control group subjects. Thus, a TBP was adequate for the management of postoperative pain following mandibular resection and reconstruction.
透皮丁丙诺啡用于术后疼痛的管理。其在下颌骨切除与重建术后疼痛管理中的有效性尚未得到评估。
评估透皮丁丙诺啡贴剂(TBP)在下颌骨切除并用髂嵴移植重建术后疼痛管理中的疗效。
研究设计、设置与样本:这项三盲随机对照试验纳入了30名年龄在18至60岁之间患有下颌骨良性病变的受试者。印度布巴内斯瓦尔全印医学科学研究所牙科门诊部的受试者被纳入研究。排除对任何药物已知过敏、使用镇静剂、饮酒、怀孕和哺乳期母亲以及有呼吸问题的受试者。
预测变量为术后疼痛管理,受试者被随机分配至TBP组或安慰剂贴剂组。
为术后疼痛,通过视觉模拟量表(VAS)连续7天进行测量。次要结局变量为急救镇痛药的需求和药物相关不良反应。
手术时年龄、性别、诊断、手术持续时间以及手术期间使用的芬太尼量为协变量。
采用描述性统计、曼-惠特尼U检验、χ检验、重复测量方差分析和事后分析(邦费罗尼检验)。P值<.05被认为具有统计学意义。
30名受试者被随机分配至TBP组和对照组。研究期间,TBP组和对照组受试者的平均VAS评分别分为0.8±2.37和3.49±2.37(P<.001)。与对照组相比,TBP组受试者直至术后第4天结束时的平均VAS评分显著更低(P<.001)。术后期间,TBP组和对照组受试者的平均急救镇痛药需求量分别为5.33±15.8毫克和47.6±37.7毫克(P<.001)。恶心是两组受试者中最常见的药物相关不良反应(46.7%)(P>.9)。
TBP组受试者术后第1天早晨的最高VAS评分为1.53±0.92,而对照组受试者术后6小时的最高VAS评分为6.47±1.3。因此,TBP足以用于下颌骨切除与重建术后的疼痛管理。